| Literature DB >> 32126078 |
Iliano V Coutinho-Abreu1, Tiago D Serafim1, Claudio Meneses1, Shaden Kamhawi1, Fabiano Oliveira1, Jesus G Valenzuela1.
Abstract
BACKGROUND: Leishmaniasis is a vector-borne neglected disease. Inside the natural sand fly vector, the promastigote forms of Leishmania undergo a series of extracellular developmental stages to reach the infectious stage, the metacyclic promastigote. There is limited information regarding the expression profile of L. infantum developmental stages inside the sand fly vector, and molecular markers that can distinguish the different parasite stages are lacking. METHODOLOGY/PRINCIPALEntities:
Year: 2020 PMID: 32126078 PMCID: PMC7053709 DOI: 10.1371/journal.pntd.0008014
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Parasite growth and overall analysis of Leishmania sequencing.
A. Phase contrast images of the Leishmania parasites at different stages obtained from midguts at different time points. B. Principal component analysis (PCA) describing the position of each Leishmania time point in the expression space. Expression space was generated based on the log2 TPMs (transcripts per million) of the significantly differentially expressed transcripts across six time points. The Eigenvalues and % variance for PC1 and PC2 were 806.1 and 70.58% and 174.6 and 15.3%, respectively. C. Total number of differentially expressed transcripts between Leishmania time points. D. Enrichment of DE transcripts for each Leishmania stage in pairwise comparisons, as color coded in the legend. E. Venn diagrams depicting the number of DE transcripts unique and shared amongst pairwise comparisons of Leishmania stages. DE was considered significant for transcripts displaying FDR (false discovery rate) q-value lower than 0.05 and LFC (log2 fold change) either lower than -0.5 or higher than 0.5. PRO2d: procyclics at day 2. NEC4d: nectomonds at day 4. LEP6d: leptomonads 6 at days. LEP8d: leptomonads at 8 days. MET12d: metacyclics at day 12. MET14d: metacyclics at day 14.
Fig 2Analysis of differentially expressed (DE) transcript enrichment in different Leishmania stages.
A. Principal Component Analysis (PCA) analysis of all the DE transcripts in all time points based on the log2 fold change (LFC) of every pairwise combination of Leishmania time points. Each quadrant in the expression space was label from 1st to 4th and the transcripts mapped to the respective quadrants were color coded in Spring Green (1st), Dodge Blue (2nd), Blue Violet (3rd), and Red (4th). The Eigenvalues and % variance for PC1 and PC2% were 20.69 and 95.35% and 0.68 and 3.15%, respectively. B. Expression analysis per quadrant. The average TPM across time points for every DE transcript mapped in each quadrant was plotted. Horizontal bars indicate median values and differences were statistically significant (* Mann Whitney test, p < 0.0001). Color coding as in A. C. Expression analysis per quadrant per time point. The average TPM for each time point for every DE transcript mapped in each quadrant was plotted. Mean TPM as shapes and SEM (standard error of mean) bars are depicted. Based on the differences observed in B and C, the quadrants in A were labeled to describe the up-regulated transcripts expressed in high and low abundance (as defined by PC1) and expressed early and late time points (as defined by PC2). D-F. Leishmania DE transcripts up-regulated in each stage mapped onto the expression space. D. Bubble plot mapping the procyclic up-regulated transcripts (Royal blue) and the nectomonad up-regulated ones (Sea green) on the transcriptional space. Scale in gray represents the log2 fold change corresponding to the diamenter of the bubbles. E. Bubble plot mapping the nectomonad up-regulated ones (Sea green) and the leptomonad up-regulated ones (Saddle brown) on the transcriptional space. F. Bubble plot mapping the leptomonad up-regulated ones (Saddle brown) and the metacyclic up-regulated ones (Fuchsia) on the transcriptional space. Differences were statistically significant at p < 0.001 (Chi-square test). DE was considered significant for transcripts displaying FDR q-value lower than 0.05 and LFC either lower than -0.5 or higher than 0.5. PRO2d: procyclics at day 2. NEC4d: nectomonds at day 4. LEP6d: leptomonads at 6 days. MET14d: metacyclics at day 14.
Fig 3Heatmap depicting temporal expression of selected DE genes.
A. Genes encoding histone proteins. H1: histone H1. H2A: histone H2A; H2B: histone H2B; H3: histone H3. H4: histone H4. B. Metacyclogenesis-related genes. HASPa: hydrophilic acylated surface protein a; HASPb: hydrophilic acylated surface protein b; SHERP: small hydrophilic endoplasmic reticulum-associated protein; META1: META domain-containing protein. C. Genes involved in phosphoconjugate sythesis. Arabinosyl: phosphoglycan beta 1,2 arabinosyltransferase; Glycosyl: glycosyltransferase family-like protein; Galactosyl: phosphoglycan beta 1,3 galactosyltransferase; Mannosyl: mannosyltransferase-like protein; PPG4: proteophosphoglycan; LPG3: glucose regulated protein 94. GenBank gene Ids and color intensity scale are also depicted on the left. PRO2d: procyclics at day 2; NEC4d: nectomonads at day 4; LEP6d: leptomonads at day 6; LEP8d: leptomonads at day 8; MET12d: metacyclics at day 12; MET14d: metacyclics at day 14.
Fig 4Chromosome displaying at least three-fold enrichment of DE genes across time Leishmania stages.
A. Chromosomes displaying enrichment of DE genes from the procyclic to the nectomonad stage. B. Chromosomes exhibiting decrease in the proportion of DE genes from the procyclic to the nectomonad stage. C. Chromosomes displaying enrichment of DE genes from leptomonad to metacyclic stage. D. Chromosomes exhibiting decrease in the proportion of DE genes from the leptomonad to the metacyclic stage. PRO2d: procyclics at day 2. NEC4d: nectomonds at day 4. LEP6d: leptomonads at 6 days. MET14d: metacyclics at day 14.
Fig 5Candidate Leishmania stage-specific markers.
Venn diagrams highlighting (in white) the numbers of DE genes between (A) procyclics, (B) nectomonad, (C) leptomonad, and (D) metacyclic. E. Overall expression profile patterns of the candidate Leishmania stage-specific markers. Number of candidate genes per stage are shown in the inset. PRO2d: procyclics at day 2. NEC4d: nectomonds at day 4. LEP6d: leptomonads 6 at days. LEP8d: leptomonads at 8 days. MET12d: metacyclics at day 12. MET14d: metacyclics at day 14.
Selected stage-specific up-regulated-genes encoding membrane proteins.
| Stage | GeneID | Locustag | NR best match | Description | e-value | log2 FC PRO2d vs NEC4d | log2 FC PRO2d vs LEP6d | log2 FC PRO2d vs MET14d |
|---|---|---|---|---|---|---|---|---|
| XM_001462976.2 | LINJ_05_0510 | XP_001463014.1 | ATPase alpha subunit | 0 | 0.777 | 0.896 | 1.197 | |
| XM_001465345.1 | LINJ_21_0770 | XP_001465382.1 | ATP-binding cassette protein subfamily E, member 1 | 0 | 0.854 | 1.243 | 1.430 | |
| XM_001462819.1 | LINJ_04_0180 | XP_001462856.1 | surface antigen-like protein | 0 | -2.862 | -0.888 | 1.435 | |
| XM_001462818.1 | LINJ_04_0170 | XP_001462855.1 | surface antigen-like protein | 0 | -2.869 | -0.763 | 1.308 | |
| XM_001462821.1 | LINJ_04_0200 | XP_001462858.1 | surface antigen-like protein | 0 | -1.915 | -1.500 | 1.080 | |
| XM_001463438.1 | LINJ_09_0180 | XP_001463475.1 | putative ATG8/AUT7/APG8/PAZ2 | 1E-90 | -2.343 | -0.739 | 0.890 | |
| XM_001468504.1 | LINJ_34_1710 | XP_001468541.1 | putative amastin-like surface protein | 1.00E-136 | -1.188 | -1.221 | -0.639 | |
| XM_001468506.2 | LINJ_34_1720 | XP_001468543.2 | putative amastin-like surface protein | 0 | -1.090 | -0.958 | -0.705 | |
| XM_001468449.1 | LINJ_34_1150 | XP_001468486.1 | putative amastin-like surface protein | 7.00E-139 | -1.694 | -0.842 | -0.719 | |
| XM_001468507.1 | LINJ_34_1730 | XP_001468544.1 | putative amastin-like surface protein | 6.00E-138 | -0.957 | -0.974 | -0.798 | |
| XM_001468501.1 | LINJ_34_1680 | XP_001468538.1 | putative amastin-like surface protein | 2.00E-149 | -1.476 | -1.135 | -0.893 | |
| XM_001468436.1 | LINJ_34_1020 | XP_001468473.1 | putative amastin-like surface protein | 7.00E-123 | -1.696 | -0.801 | -0.659 | |
| XM_001468503.1 | LINJ_34_1700 | XP_001468540.1 | putative amastin-like surface protein | 6.00E-136 | -1.681 | -1.651 | -1.211 | |
| XM_003392619.1 | LINJ_28_0610 | XP_003392668.1 | putative leishmanolysin | 0 | -2.214 | -1.447 | -0.692 | |
| XM_001463664.2 | LINJ_10_0520 | XP_001463701.2 | GP63, leishmanolysin | 0 | -2.896 | -1.470 | -0.707 | |
| XM_001463660.2 | LINJ_10_0530 | XP_001463697.2 | GP63, leishmanolysin | 0 | -4.894 | -3.188 | -1.206 | |
| XM_003392666.1 | LINJ_31_1850 | XP_003392714.1 | amino acid permease | 0 | -1.586 | -1.535 | -0.870 | |
| XM_003392664.1 | LINJ_31_1810 | XP_003392712.1 | amino acid permease | 0 | -2.249 | -2.161 | -0.762 | |
| XM_001469645.1 | LINJ_36_3500 | XP_001469682.1 | hypothetical transmembrane protein | 0 | -1.220 | -1.044 | -0.531 | |
| XM_001462682.1 | LINJ_02_0270 | XP_001462719.1 | LOW QUALITY PROTEIN: putative ABC1 transporter | 0 | -1.569 | -1.184 | -1.004 | |
| XM_003392265.1 | LINJ.12.0662 | XP_003392313.1 | putative surface antigen protein 2 | 2.00E-155 | -2.536 | -1.736 | -1.170 | |
| XM_001463964.2 | LINJ.12.0670 | XP_001464001.2 | putative surface antigen protein 2 | 0 | -3.113 | -2.369 | -1.261 | |
| XM_003392269.1 | LINJ.12.0666 | XP_003392317.1 | putative surface antigen protein 2 | 0 | -3.771 | -2.919 | -1.498 | |
| XM_003392274.1 | LINJ.12.0690 | XP_003392322.1 | surface antigen protein 2 precursor | 0 | -3.653 | -1.558 | -1.105 |
Selected top stage-specific markers displaying the highest fold change compared to the next stage.
| Stage | GeneID | Locustag | NR best match | Description | e-value | log2 FC PRO2d vs NEC4d | log2 FC PRO2d vs LEP6d | log2 FC PRO2d vs MET14d |
|---|---|---|---|---|---|---|---|---|
| XM_001463562.1 | LINJ_09_0660 | XP_001463599.1 | conserved hypothetical protein | 7.00E-143 | 2.050 | 1.635 | 0.983 | |
| XM_001469684.1 | LINJ_09_1420 | XP_001469721.1 | conserved hypothetical protein | 0 | 1.939 | 1.315 | 1.694 | |
| XM_001466644.1 | XM_001466644.1 | XP_001466681.1 | conserved hypothetical protein | 0 | 1.772 | 1.778 | 2.234 | |
| XM_001470194.1 | LINJ_28_2060 | XP_001470231.1 | putative zinc transporter | 0 | 1.565 | 2.237 | 2.230 | |
| XM_003392629.1 | LINJ_28_2060 | XP_001470231.1 | putative zinc transporter | 0 | 1.565 | 2.237 | 2.230 | |
| XM_001463906.2 | LINJ_29_1600 | XP_001463943.2 | conserved hypothetical protein | 0 | 1.499 | 1.043 | 1.678 | |
| XM_001468347.1 | LINJ_33_3390 | XP_001468384.1 | h1 histone-like protein | 4.00E-83 | 1.470 | 1.229 | 2.101 | |
| XM_001467545.1 | LINJ_31_2650 | XP_001467582.1 | ubiquinol-cytochrome-c reductase-like protein | 5.00E-44 | 1.456 | 1.769 | 2.260 | |
| XM_003392567.1 | LINJ_26_0990 | XP_003392615.1 | hypothetical protein LINJ_26_0990 | 2.00E-40 | 1.453 | 1.715 | 0.857 | |
| XM_001466147.1 | LINJ_25_1530 | XP_001466184.1 | cyclin | 0 | 1.449 | 1.143 | 1.718 | |
| XM_001462831.1 | LINJ_04_0300 | XP_001462868.1 | putative beta-fructofuranosidase | 0 | -0.664 | 0.930 | 2.124 | |
| XM_001466274.1 | LINJ_27_0430 | XP_001466311.1 | putative ribokinase | 0 | -0.805 | 0.853 | 0.610 | |
| XM_003392396.1 | LINJ_20_1730 | XP_003392444.1 | putative N-acyl-L-amino acid amidohydrolase | 0 | -2.658 | 0.649 | 1.925 | |
| XM_001464164.1 | LINJ_14_0180 | XP_001464201.1 | metallo-peptidase, Clan MA(E), Family M32 | 0 | -0.793 | 0.607 | 1.132 | |
| XM_001462905.1 | LINJ_04_1030 | XP_001462942.1 | conserved hypothetical protein | 1.00E-136 | -1.149 | 0.505 | 1.236 | |
| XM_001462819.1 | LINJ_04_0180 | XP_001462856.1 | surface antigen-like protein | 0 | -2.863 | -0.889 | 1.435 | |
| XM_001462818.1 | LINJ_04_0170 | XP_001462855.1 | surface antigen-like protein | 0 | -2.870 | -0.764 | 1.309 | |
| XM_001466805.1 | LINJ_30_0290 | XP_001466842.1 | hypothetical protein, unknown function | 0 | -0.963 | -0.595 | 1.102 | |
| XM_001462821.1 | LINJ_04_0200 | XP_001462858.1 | surface antigen-like protein | 0 | -1.916 | -1.500 | 1.081 | |
| XM_003392407.1 | LINJ_21_1100 | XP_003392455.1 | putative mis-match repair protein | 0 | -1.930 | -0.657 | 0.900 | |
| XM_001463438.1 | LINJ_09_0180 | XP_001463475.1 | putative ATG8/AUT7/APG8/PAZ2 | 1.00E-90 | -2.343 | -0.739 | 0.891 | |
| XM_001470568.1 | LINJ_26_2710 | XP_001470605.1 | hypothetical protein, unknown function | 0 | -2.445 | -0.723 | 0.885 | |
| XM_001464501.1 | LINJ_16_0500 | XP_001464538.1 | conserved hypothetical protein | 3.00E-142 | -1.433 | -0.605 | 0.867 | |
| XM_001465134.2 | LINJ_20_1220 | XP_001465171.2 | putative calpain-like cysteine peptidase | 0 | -9.404 | -0.903 | 0.781 | |
| XM_001468097.1 | LINJ_33_0530 | XP_001468134.1 | putative d-xylulose reductase | 0 | -0.833 | -1.751 | 0.701 | |
| XM_003392269.1 | LINJ.12.0666 | XP_003392317.1 | putative surface antigen protein 2 | 0 | -3.771 | -2.920 | -1.498 | |
| XM_001466148.1 | LINJ_25_1540 | XP_001466185.1 | calpain family cysteine protease-like protein | 0 | -3.209 | -2.614 | -1.303 | |
| XM_001463964.2 | XP_001464001.2 | putative surface antigen protein 2 | 0 | -3.114 | -2.369 | -1.262 | ||
| XM_001467534.1 | LINJ_31_2540 | XP_001467571.1 | putative lipase | 0 | -2.277 | -2.208 | -1.221 | |
| XM_001468503.1 | LINJ_34_1700 | XP_001468540.1 | putative amastin-like surface protein | 6.00E-136 | -1.681 | -1.652 | -1.212 | |
| XM_001463660.2 | LINJ_10_0530 | XP_001463697.2 | GP63, leishmanolysin | 0 | -4.895 | -3.188 | -1.207 | |
| XM_001464983.1 | LINJ_19_0570 | XP_001465020.1 | conserved hypothetical protein | 0 | -3.217 | -2.002 | -1.175 | |
| XM_003392265.1 | LINJ.12.0662 | XP_003392313.1 | putative surface antigen protein 2 | 2.00E-155 | -2.537 | -1.736 | -1.170 | |
| XM_003392196.1 | LINJ_08_1220 | XP_003392244.1 | hypothetical protein, unknown function | 0 | -0.604 | -1.078 | -1.130 | |
| XM_003392274.1 | LINJ.12.0690 | XP_003392322.1 | surface antigen protein 2 precursor | 0 | -3.654 | -1.559 | -1.106 |